ライフサイエンスコーパス: GlaxoSmithKline

1 se of bivalent HPV vaccine (2vHPV; Cervarix, GlaxoSmithKline).

2 egistry maintained by the drug manufacturer (GlaxoSmithKline).

3 identical to those of DELSM manufactured by GlaxoSmithKline.

4 ion, the Roger de Spoelberch Foundation, and GlaxoSmithKline.

5 National Institute for Health Research, GlaxoSmithKline.

6 ubunit protein vaccine candidate provided by GlaxoSmithKline.

7 iclovir was provided for trial 3 for free by GlaxoSmithKline.

8 Hospital Center and by a research grant from GlaxoSmithKline.

9 ntroduce the oral rotavirus vaccine Rotarix (GlaxoSmithKline), 1 of 2 recently developed vaccines aga

10 se (MEK) inhibitors (PD0325901 or trametinib/GlaxoSmithKline 1120212) significantly prolonged surviva

11 t reverse transcriptase inhibitor (retrovir, GlaxoSmithKline, 1987).

12 Rotarix (GlaxoSmithKline), a newly licensed rotavirus vaccine req

13 d with recombinant ASP-2 formulated with the GlaxoSmithKline Adjuvant, AS03.

14 efficacy studies (assessing the 3-component GlaxoSmithKline and 5-component Sanofi-Pasteur formulati

15 Two live oral vaccines being prepared by GlaxoSmithKline and Merck have completed large-scale cli

16 d to model 5-HT type 3 antagonist (Lotronex, GlaxoSmithKline) and 5-HT type 4 agonist (Zelnorm, Novar

17 received oral valacyclovir 2 g tid (Valtrex, GlaxoSmithKline) and one patient with impaired renal fun

18 UK Medical Research Council, GlaxoSmithKline, and British Heart Foundation.

19 misation list that was computer generated at GlaxoSmithKline, and was stratified, in a block size of

20 oratories in the nonprofit sector, Merck and GlaxoSmithKline are developing commercial versions of th

21 Council (grant number G1000417/94909), ICON, GlaxoSmithKline, AstraZeneca, and the Medical Evaluation

22 GlaxoSmithKline, Bill & Melinda Gates Foundation, Partne

23 and Ministry of Health of Costa Rica (CVT); GlaxoSmithKline Biologicals SA (PATRICIA).

24 GlaxoSmithKline Biologicals SA and PATH Malaria Vaccine

25 formulated using the AS01B Adjuvant System (GlaxoSmithKline Biologicals).

26 n influenza A(H1N1)pdm09 vaccine (Pandemrix; GlaxoSmithKline Biologicals).

27 Vaccine Group, University of Oxford, UK; and GlaxoSmithKline Biologicals, Belgium.

28 NIHR Oxford Biomedical Research Centre and GlaxoSmithKline Biologicals.

29 Vaccine was provided by GlaxoSmithKline Biologicals.

30 is Vaccines and Diagnostics), AS03 and AS04 (GlaxoSmithKline Biologics), AF03 (Sanofi), and liposomes

31 ception occurring after Rotarix vaccination (GlaxoSmithKline Biologics, Research Triangle Park, North

32 l population structure and vaccine (Bexsero, GlaxoSmithKline, Brentford, Middlesex, UK) antigen varia

33 ivated protein kinase inhibitor (Losmapimod; GlaxoSmithKline, Brentford, United Kingdom), which reduc

34 oehringer Ingelheim, Novartis, and Sepracor; GlaxoSmithKline; Centers for Medicare and Medicaid Servi

35 1:1-134, 2009 and GlaxoSmithKline clinical documents related to acyclovir.

36 We searched MEDLINE, the GlaxoSmithKline clinical trials register, the US Food an

37 eidentified individual participant data from GlaxoSmithKline clinical trials were obtained through Cl

38 cted at a specialist early psychosis clinic, GlaxoSmithKline Clinical Unit, and magnetic resonance im

39 djuvanted H1N1 influenza vaccine (Pandemrix [GlaxoSmithKline]) during pregnancy.

40 Additionally, the GlaxoSmithKline family of adjuvants AS01B, AS02A, and AS

41 nal Development, the Rockefeller Foundation, GlaxoSmithKline, Gilead Sciences, Boehringer-Ingelheim,

42 es and Diagnostics division (now part of the GlaxoSmithKline group of companies), Wellcome Trust UK,

43 es and Diagnostics division, now part of the GlaxoSmithKline group of companies.

44 omized controlled trials (RCTs) conducted by GlaxoSmithKline (GSK) and the NCIC Clinical Trials Group

45 ical study (BAT117213 study) is sponsored by GlaxoSmithKline (GSK) with associated exploratory studie

46 tween the University of Nottingham (UoN) and GlaxoSmithKline (GSK).

47 says of 631 diverse chemicals proprietary to GlaxoSmithKline (GSK).

48 women, were combined in a post-hoc analysis (GlaxoSmithKline [GSK] e-track number 202142) to investig

49 The CRAC channel blocker developed by GlaxoSmithKline, GSK-7975A, inhibited store-operated Ca(

50 GlaxoSmithKline has recently disclosed the results of a

51 ew Cruzipain inhibitory scaffolds within the GlaxoSmithKline HAT (Human African Trypanosomiasis) and

52 d at SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) have allowed us to analyze the relative

53 Using whole-cell phenotypic assays, the GlaxoSmithKline high-throughput screening (HTS) diversit

54 independent case-control studies of MDD: the GlaxoSmithKline-High-Throughput Disease-specific target

55 (6/21 [29%]), intradermal IPV (9/16 [56%]), GlaxoSmithKline intramuscular IPV (19/22 [86%]), and Pan

56 egative, 42 (100%) of 42 seroconverted after GlaxoSmithKline intramuscular IPV, and 24 (59%) of 41 af

57 al Science Foundation, Leenaards Foundation, GlaxoSmithKline, Ligue Pulmonaire Vaudoise.

58 ction of a replacement MMR vaccine (Priorix; GlaxoSmithKline, London, United Kingdom) in 1998, active

59 number G1000417/94909), ICON, Astra Zeneca, GlaxoSmithKline, Medicines Evaluation Unit).

60 GlaxoSmithKline, Medicines for Malaria Venture.

61 GlaxoSmithKline; National Institutes of Health; and Mayo

62 ger Ingelheim (Germany and Canada), Servier, GlaxoSmithKline, Novartis, King Pharma, and national or

63 ger Ingelheim (Germany and Canada), Servier, GlaxoSmithKline, Novartis, King Pharma, and national or

64 l-dose IPV from two different manufacturers (GlaxoSmithKline or Panacea).

65 al-dose inactivated poliovirus vaccine (IPV, GlaxoSmithKline), or intramuscular full-dose IPV from tw

66 and Genomic Epidemiology (ENGAGE) and Oxford-GlaxoSmithKline (Ox-GSK) consortia to follow up the 15 m

67 ared the efficacy of rosiglitazone (Avandia; GlaxoSmithKline, Philadelphia, PA) 4 mg orally twice dai

68 FabI inhibitors began with screening of the GlaxoSmithKline proprietary compound collection, which i

69 rough high-throughput screening (HTS) of the GlaxoSmithKline proprietary compound collection.

70 ibitors from a high throughput screen of the GlaxoSmithKline proprietary compound collection.

71 GlaxoSmithKline, Prosensa Therapeutics BV (a subsidiary

72 GlaxoSmithKline R&D and the Medical Research Council.

73 one-based interactive voice-response system (GlaxoSmithKline Registration and Medication Ordering Sys

74 Randomisation was done by the GlaxoSmithKline Registration and Medication Ordering Sys

75 Randomisation was done by the GlaxoSmithKline Registration/Medication Ordering System

76 y assigned to standard therapy (Nicoderm CQ [GlaxoSmithKline, Research Triangle Park, North Carolina]

77 d (1:1) to receive an HPV vaccine (Cervarix, GlaxoSmithKline, Rixensart, Belgium) or a control hepati

78 s A vaccine (modified preparation of Havrix, GlaxoSmithKline, Rixensart, Belgium).

79 ree-step asymmetric and racemic syntheses of GlaxoSmithKline's highly potent PDE IVb inhibitor 1 were

80 ncluding stratification, was generated using GlaxoSmithKline's RandAll software.

81 GlaxoSmithKline scientists have successfully optimized a

82 enter, Utrecht, Novo Nordisk, Astra, Pfizer, GlaxoSmithKline, Servier, HemoCue, Merck.

83 We established the Oxford-GlaxoSmithKline study (Ox-GSK) to perform a genome-wide

84 From the GlaxoSmithKline trial registry, we selected randomised,

85 The GlaxoSmithKline vaccine has been licensed in Mexico and